Compare Stocks: CBIO, QURE, BEAM, and IMNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$23.82 -0.7%	$28.28	$20.23 ▼ $38.26	$2.48B	2.22	1.81 million shs	1.46 million shs
CBIO Crescent Biopharma	$19.84 +2.2%	$17.08	$8.72 ▼ $27.41	$720.97M	1.24	261,703 shs	251,176 shs
IMNM Immunome	$24.64 -0.1%	$25.34	$8.93 ▼ $30.06	$2.80B	2.13	982,553 shs	744,600 shs
QURE uniQure	$45.00 +1.1%	$44.43	$8.73 ▼ $71.50	$3.09B	0.94	1.11 million shs	638,010 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.54%	-18.68%	-9.83%	-22.17%	+17.09%
CBIO Crescent Biopharma	+1.39%	-5.75%	+14.82%	+9.64%	+57.57%
IMNM Immunome	-0.49%	-8.26%	-9.74%	+37.07%	+166.56%
QURE uniQure	+0.94%	+0.97%	-7.59%	+66.47%	+172.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$23.82 -0.7%	$28.28	$20.23 ▼ $38.26	$2.48B	2.22	1.81 million shs	1.46 million shs
CBIO Crescent Biopharma	$19.84 +2.2%	$17.08	$8.72 ▼ $27.41	$720.97M	1.24	261,703 shs	251,176 shs
IMNM Immunome	$24.64 -0.1%	$25.34	$8.93 ▼ $30.06	$2.80B	2.13	982,553 shs	744,600 shs
QURE uniQure	$45.00 +1.1%	$44.43	$8.73 ▼ $71.50	$3.09B	0.94	1.11 million shs	638,010 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.54%	-18.68%	-9.83%	-22.17%	+17.09%
CBIO Crescent Biopharma	+1.39%	-5.75%	+14.82%	+9.64%	+57.57%
IMNM Immunome	-0.49%	-8.26%	-9.74%	+37.07%	+166.56%
QURE uniQure	+0.94%	+0.97%	-7.59%	+66.47%	+172.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	103.15% Upside
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	50.41% Upside
IMNM Immunome	2.85	Moderate Buy	$34.64	41.08% Upside
QURE uniQure	2.76	Moderate Buy	$65.00	44.67% Upside

Current Analyst Ratings Breakdown

Latest CBIO, QURE, BEAM, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
9/2/2026	QURE uniQure	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform
8/27/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/24/2026	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	CBIO Crescent Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$156.04M	15.97	N/A	N/A	$12.20 per share	1.98
CBIO Crescent Biopharma	$11.88M	61.52	N/A	N/A	$14.32 per share	1.37
IMNM Immunome	N/A	N/A	N/A	N/A	$5.75 per share	N/A
QURE uniQure	$16.10M	193.59	N/A	N/A	$3.19 per share	14.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)

Latest CBIO, QURE, BEAM, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.73%	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CBIO Crescent Biopharma	N/A	9.66	9.66
IMNM Immunome	N/A	15.08	15.08
QURE uniQure	0.15	10.01	10.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CBIO Crescent Biopharma	75.19%
IMNM Immunome	44.58%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CBIO Crescent Biopharma	24.84%
IMNM Immunome	7.21%
QURE uniQure	4.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
IMNM Immunome	177	113.58 million	105.39 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable

CBIO, QURE, BEAM, and IMNM Headlines

Recent News About These Companies

Engineers Gate Manager LP Sells 243,693 Shares of uniQure N.V. $QURE

September 15 at 4:07 AM | marketbeat.com

FDA expands Bayer lung cancer drug approval

September 10, 2026 | statnews.comS

What to expect from UniQure’s upcoming Huntington’s gene therapy readout

September 10, 2026 | statnews.comS

Squarepoint Ops LLC Has $12.91 Million Stock Holdings in uniQure N.V. $QURE

September 10, 2026 | marketbeat.com

uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application?

September 8, 2026 | insidermonkey.com

uniQure N.V. $QURE Shares Sold by Readystate Asset Management LP

September 7, 2026 | marketbeat.com

QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy

September 6, 2026 | ad-hoc-news.deA

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 5, 2026 | investorplace.com

Wall Street Zen Downgrades uniQure (NASDAQ:QURE) to Sell

September 5, 2026 | americanbankingnews.com

uniQure (NASDAQ:QURE) Lowered to Sell Rating by Wall Street Zen

September 5, 2026 | marketbeat.com

uniQure submits ifezuntirgene inilparvovec BLA to US FDA to treat Huntington’s disease

September 4, 2026 | pharmabiz.comP

uniQure (NASDAQ:QURE) Shares Gap Up - Here's Why

September 4, 2026 | americanbankingnews.com

uniQure (NASDAQ:QURE) Coverage Initiated at William Blair

September 4, 2026 | americanbankingnews.com

uniQure files for US and UK approval for AMT-130 in Huntington’s disease

September 3, 2026 | thepharmaletter.comT

uniQure (NASDAQ:QURE) Trading Down 4.4% - Here's Why

September 3, 2026 | marketbeat.com

QURE Submits Application for Gene Therapy for Huntington's Disease

September 3, 2026 | zacks.com

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 3, 2026 | investorplace.com

UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

September 2, 2026 | biopharmadive.comB

UniQure Submits Biologics License Application For AMT-130 In Huntington's Disease; Stock Up

September 2, 2026 | rttnews.com

Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more

September 2, 2026 | statnews.comS

uniQure Submits BLA for AMT-130 in Huntington's Disease

September 2, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, QURE, BEAM, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$23.82 -0.17 (-0.70%)

As of 09:30 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Crescent Biopharma NASDAQ:CBIO

$19.84 +0.43 (+2.19%)

As of 09:30 AM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Immunome NASDAQ:IMNM

$24.64 -0.03 (-0.12%)

As of 09:30 AM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

uniQure NASDAQ:QURE

$45.00 +0.49 (+1.10%)

As of 09:30 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBIO, QURE, BEAM, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBIO, QURE, BEAM, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBIO, QURE, BEAM, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, QURE, BEAM, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Crescent Biopharma NASDAQ:CBIO

Immunome NASDAQ:IMNM

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBIO, QURE, BEAM, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBIO, QURE, BEAM, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBIO, QURE, BEAM, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, QURE, BEAM, and IMNM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Crescent Biopharma NASDAQ:CBIO

Immunome NASDAQ:IMNM

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools